Do you really think the former Chairman of the $10 BILLION...

Do you really think the former Chairman of the $10 BILLION company Sarepta would come to this micro-cap Antisense if he didnt see monster potential ? this one has the potential to be the next Sarepta ..I LOVE ITTTTT

Former SRPT Chairman, William (Bill) Goolsbee, is a director on ANP’s Board.Goolsbee is also the Chairman of the company’s scientific advisory board which includes the two Australian scientists (Profs Steve Wilton and Sue Fletcher) who are the inventors of Sarepta’s drug, eteplirsen. Bill has extensive experience and networks in the field of DMD drug development and commercialisation which he is imparting on ANP in their development of ATL1102

Breakthrough Prize given to Antisense pioneer
https://finfeed.com/small-caps/biotech/breakthrough-prize-given-antisense-pioneer/


Forbes published an article about two winners of The Breakthrough Prizes, referred to as the ‘Oscars of Science’. Head of research at Ionis Pharmaceuticals, C. Frank Bennett, and his colleague Adrian R. Krainer will share a $3 million Breakthrough Prize for their role in developing Spinraza, a drug for spinal muscular atrophy which was invented by Ionis.

The link to ANP is the fact that the small cap has a worldwide exclusive license from Ionis for their IP on ATL1102 — and Bennett is actually the first named inventor on the original ATL1102 patents.

Ergo, one of the brains behind ANP’s ATL1102 drug candidate is the same man behind the ground-breaking Spinraza drug. Bennett also previously served as non-executive director on ANP’s board.